Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Pharmaceutical
Articles
Uncertainty over drug pipeline sends Lilly shares down
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Bristol-Myers Squibb plans 113 job cuts in southern Indiana
Drugmaker Bristol-Myers Squibb Co. plans to close one of its southern Indiana facilities and cut jobs at another.
Lilly reports $942 million profit in third quarter
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Medco plans to compare Plavix, Effient in study
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
Manchester wants doctoral pharmacology program
Manchester College officials say they want to start a pharmacy school in Fort Wayne starting in the fall of 2012.
Endocyte receives $26M infusion from investors
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company
continue developing cancer-fighting drugs.
Lilly to pay Idaho $13M in drug settlement
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of
anti-psychotic drug Zyprexa.
Lilly to sell Lafayette plant to German firm
Nearly 700 workers will be offered severance, new jobs
Lilly settles Zyprexa suit with S. Carolina
Eli Lilly and Co. has agreed to settle the State of South Carolina’s lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
Connecticut gets $25 million from Zyprexa lawsuit
Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
Lilly’s win in Evista patent case crucial, analyst says
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
Judge upholds Lilly’s Evista patent
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
Lilly agrees to settle more state Zyprexa suits
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
Lilly sells constipation drug to Adolor
Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.
Lilly: Alimta improves lung-cancer survival time
Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.
Local health care industry tries to capitalize on migraine headaches
Migraines cost American employers $20 billion a year in decreased worker productivity. Such
a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
UPDATE: Pipeline challenges force Lilly restructuring moves
Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.
Lilly reorganization to cut 5,500 positions over 2 years
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
Lilly paid doctors to prescribe Zyprexa, notes say
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers’ program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.